TR201605717A1 - Anti̇bakteri̇yel formülasyonlar - Google Patents
Anti̇bakteri̇yel formülasyonlar Download PDFInfo
- Publication number
- TR201605717A1 TR201605717A1 TR2016/05717A TR201605717A TR201605717A1 TR 201605717 A1 TR201605717 A1 TR 201605717A1 TR 2016/05717 A TR2016/05717 A TR 2016/05717A TR 201605717 A TR201605717 A TR 201605717A TR 201605717 A1 TR201605717 A1 TR 201605717A1
- Authority
- TR
- Turkey
- Prior art keywords
- sodium
- pharmaceutical composition
- feature
- flavor
- specified
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 47
- 230000000844 anti-bacterial effect Effects 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 33
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 13
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 13
- 229930186147 Cephalosporin Natural products 0.000 claims abstract description 12
- 229940124587 cephalosporin Drugs 0.000 claims abstract description 12
- 150000001780 cephalosporins Chemical class 0.000 claims abstract description 12
- 208000015181 infectious disease Diseases 0.000 claims abstract description 10
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 5
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- 206010005940 Bone and joint infections Diseases 0.000 claims abstract description 4
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims abstract description 4
- 206010033078 Otitis media Diseases 0.000 claims abstract description 4
- 201000007100 Pharyngitis Diseases 0.000 claims abstract description 4
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 4
- 206010040047 Sepsis Diseases 0.000 claims abstract description 4
- 206010062255 Soft tissue infection Diseases 0.000 claims abstract description 4
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims abstract description 4
- 201000003146 cystitis Diseases 0.000 claims abstract description 4
- 206010014665 endocarditis Diseases 0.000 claims abstract description 4
- 206010034674 peritonitis Diseases 0.000 claims abstract description 4
- 201000007094 prostatitis Diseases 0.000 claims abstract description 4
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims abstract description 4
- 208000013223 septicemia Diseases 0.000 claims abstract description 4
- 206010040872 skin infection Diseases 0.000 claims abstract description 4
- 206010044008 tonsillitis Diseases 0.000 claims abstract description 4
- 208000019206 urinary tract infection Diseases 0.000 claims abstract description 3
- 239000000796 flavoring agent Substances 0.000 claims description 40
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 36
- 235000019634 flavors Nutrition 0.000 claims description 34
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- -1 cefkapen Chemical compound 0.000 claims description 23
- 238000005469 granulation Methods 0.000 claims description 22
- 230000003179 granulation Effects 0.000 claims description 22
- 229930006000 Sucrose Natural products 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- 239000005720 sucrose Substances 0.000 claims description 17
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 16
- 235000010234 sodium benzoate Nutrition 0.000 claims description 16
- 239000004299 sodium benzoate Substances 0.000 claims description 16
- 229940106164 cephalexin Drugs 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 239000000377 silicon dioxide Substances 0.000 claims description 12
- 229960000999 sodium citrate dihydrate Drugs 0.000 claims description 12
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 10
- 244000007835 Cyamopsis tetragonoloba Species 0.000 claims description 10
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 10
- 240000009088 Fragaria x ananassa Species 0.000 claims description 10
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 10
- 229920000926 Galactomannan Polymers 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 10
- 235000010493 xanthan gum Nutrition 0.000 claims description 10
- 239000000230 xanthan gum Substances 0.000 claims description 10
- 229920001285 xanthan gum Polymers 0.000 claims description 10
- 229940082509 xanthan gum Drugs 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000314 lubricant Substances 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 229940047526 cephalexin monohydrate Drugs 0.000 claims description 7
- YGZIWEZFFBPCLN-UHFFFAOYSA-N n,3-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OOC1CCOP(=O)(NCCCl)N1CCCl YGZIWEZFFBPCLN-UHFFFAOYSA-N 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- 239000006172 buffering agent Substances 0.000 claims description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 6
- 235000019441 ethanol Nutrition 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000000454 talc Substances 0.000 claims description 6
- 229910052623 talc Inorganic materials 0.000 claims description 6
- 235000012222 talc Nutrition 0.000 claims description 6
- 229960004106 citric acid Drugs 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 235000019198 oils Nutrition 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims description 4
- 239000005995 Aluminium silicate Substances 0.000 claims description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 4
- 240000000560 Citrus x paradisi Species 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 235000012211 aluminium silicate Nutrition 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 235000013539 calcium stearate Nutrition 0.000 claims description 4
- 239000008116 calcium stearate Substances 0.000 claims description 4
- 229940078456 calcium stearate Drugs 0.000 claims description 4
- 235000020971 citrus fruits Nutrition 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- 229960003885 sodium benzoate Drugs 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 235000010199 sorbic acid Nutrition 0.000 claims description 4
- 239000004334 sorbic acid Substances 0.000 claims description 4
- 229940075582 sorbic acid Drugs 0.000 claims description 4
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 claims description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004418 trolamine Drugs 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 229960004274 stearic acid Drugs 0.000 claims description 3
- 210000002229 urogenital system Anatomy 0.000 claims description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- NEEKVKZFYBQFGT-BTJKTKAUSA-N 9-amino-1,2,3,4-tetrahydroacridin-1-ol;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1=CC=C2C(N)=C(C(O)CCC3)C3=NC2=C1 NEEKVKZFYBQFGT-BTJKTKAUSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 244000144730 Amygdalus persica Species 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 2
- 241000207199 Citrus Species 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 235000019501 Lemon oil Nutrition 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000004368 Modified starch Substances 0.000 claims description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019502 Orange oil Nutrition 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 2
- 241001092459 Rubus Species 0.000 claims description 2
- 235000017848 Rubus fruticosus Nutrition 0.000 claims description 2
- 240000007651 Rubus glaucus Species 0.000 claims description 2
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 2
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 2
- 239000004115 Sodium Silicate Substances 0.000 claims description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000001744 Sodium fumarate Substances 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 2
- 229940063655 aluminum stearate Drugs 0.000 claims description 2
- 229940011037 anethole Drugs 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- 229960003872 benzethonium Drugs 0.000 claims description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 229960004365 benzoic acid Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 235000021029 blackberry Nutrition 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 229960002645 boric acid Drugs 0.000 claims description 2
- 235000010338 boric acid Nutrition 0.000 claims description 2
- 229940067596 butylparaben Drugs 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- ILWNTWRKKKGJCG-UHFFFAOYSA-L calcium;sulfate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]S([O-])(=O)=O ILWNTWRKKKGJCG-UHFFFAOYSA-L 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- HOGISBSFFHDTRM-GHXIOONMSA-N cefdaloxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/O)\C1=CSC(N)=N1 HOGISBSFFHDTRM-GHXIOONMSA-N 0.000 claims description 2
- 229950006550 cefdaloxime Drugs 0.000 claims description 2
- 229960003719 cefdinir Drugs 0.000 claims description 2
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims description 2
- 229960004069 cefditoren Drugs 0.000 claims description 2
- KMIPKYQIOVAHOP-YLGJWRNMSA-N cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 claims description 2
- 229960004041 cefetamet Drugs 0.000 claims description 2
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 claims description 2
- 229960002129 cefixime Drugs 0.000 claims description 2
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims description 2
- 229960003791 cefmenoxime Drugs 0.000 claims description 2
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 claims description 2
- 229960004682 cefoperazone Drugs 0.000 claims description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 2
- 229960004261 cefotaxime Drugs 0.000 claims description 2
- 229960000484 ceftazidime Drugs 0.000 claims description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims description 2
- 229960004755 ceftriaxone Drugs 0.000 claims description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 2
- 229920003086 cellulose ether Polymers 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 229960002242 chlorocresol Drugs 0.000 claims description 2
- 235000017803 cinnamon Nutrition 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- 229940043237 diethanolamine Drugs 0.000 claims description 2
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 claims description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 claims description 2
- 229940043276 diisopropanolamine Drugs 0.000 claims description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 2
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229960001484 edetic acid Drugs 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 229960004667 ethyl cellulose Drugs 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229940012017 ethylenediamine Drugs 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 229930190179 eucalyptal Natural products 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 229940014259 gelatin Drugs 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 229960000443 hydrochloric acid Drugs 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 239000000905 isomalt Substances 0.000 claims description 2
- 235000010439 isomalt Nutrition 0.000 claims description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 229960000448 lactic acid Drugs 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000010501 lemon oil Substances 0.000 claims description 2
- 231100000518 lethal Toxicity 0.000 claims description 2
- 230000001665 lethal effect Effects 0.000 claims description 2
- 235000005772 leucine Nutrition 0.000 claims description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960003194 meglumine Drugs 0.000 claims description 2
- 229940041616 menthol Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960001047 methyl salicylate Drugs 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 239000008368 mint flavor Substances 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- 229960002446 octanoic acid Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 239000007968 orange flavor Substances 0.000 claims description 2
- 239000010502 orange oil Substances 0.000 claims description 2
- JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 claims description 2
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 claims description 2
- 239000010663 parsley oil Substances 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 229920000570 polyether Polymers 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 239000001508 potassium citrate Substances 0.000 claims description 2
- 229960002635 potassium citrate Drugs 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 235000011082 potassium citrates Nutrition 0.000 claims description 2
- 229940096992 potassium oleate Drugs 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 235000019814 powdered cellulose Nutrition 0.000 claims description 2
- 229920003124 powdered cellulose Polymers 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- 235000010388 propyl gallate Nutrition 0.000 claims description 2
- 229940075579 propyl gallate Drugs 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 235000002020 sage Nutrition 0.000 claims description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 229940001607 sodium bisulfite Drugs 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 229940001593 sodium carbonate Drugs 0.000 claims description 2
- 229960002668 sodium chloride Drugs 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- 229960001790 sodium citrate Drugs 0.000 claims description 2
- 235000011083 sodium citrates Nutrition 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 235000019294 sodium fumarate Nutrition 0.000 claims description 2
- 229940005573 sodium fumarate Drugs 0.000 claims description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 2
- 229940083608 sodium hydroxide Drugs 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 235000011008 sodium phosphates Nutrition 0.000 claims description 2
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 claims description 2
- 235000010334 sodium propionate Nutrition 0.000 claims description 2
- 239000004324 sodium propionate Substances 0.000 claims description 2
- 229960003212 sodium propionate Drugs 0.000 claims description 2
- 239000004404 sodium propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010230 sodium propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052911 sodium silicate Inorganic materials 0.000 claims description 2
- 229940032158 sodium silicate Drugs 0.000 claims description 2
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 claims description 2
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 229910002029 synthetic silica gel Inorganic materials 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 239000008371 vanilla flavor Substances 0.000 claims description 2
- 229940012185 zinc palmitate Drugs 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- LPEBYPDZMWMCLZ-CVBJKYQLSA-L zinc;(z)-octadec-9-enoate Chemical compound [Zn+2].CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O LPEBYPDZMWMCLZ-CVBJKYQLSA-L 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- GJAPSKMAVXDBIU-UHFFFAOYSA-L zinc;hexadecanoate Chemical compound [Zn+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O GJAPSKMAVXDBIU-UHFFFAOYSA-L 0.000 claims description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 235000006679 Mentha X verticillata Nutrition 0.000 claims 1
- 235000002899 Mentha suaveolens Nutrition 0.000 claims 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims 1
- 240000008790 Musa x paradisiaca Species 0.000 claims 1
- 239000000908 ammonium hydroxide Substances 0.000 claims 1
- 229940043379 ammonium hydroxide Drugs 0.000 claims 1
- 235000011114 ammonium hydroxide Nutrition 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 229960004838 phosphoric acid Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 239000009637 wintergreen oil Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 6
- 206010061182 Genitourinary tract infection Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 description 19
- AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 239000008187 granular material Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 238000007906 compression Methods 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 238000007908 dry granulation Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000002132 β-lactam antibiotic Substances 0.000 description 3
- 229940124586 β-lactam antibiotics Drugs 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XSPUSVIQHBDITA-KXDGEKGBSA-N (6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CN1N=NC(C)=N1 XSPUSVIQHBDITA-KXDGEKGBSA-N 0.000 description 1
- NWWJFMCCTZLKNT-UHFFFAOYSA-N 3,4-dihydro-2h-thiazine Chemical compound C1CC=CSN1 NWWJFMCCTZLKNT-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000228431 Acremonium chrysogenum Species 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 241000228417 Sarocladium strictum Species 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 125000003460 beta-lactamyl group Chemical group 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- LNZMRLHZGOBKAN-KAWPREARSA-N cefpimizole Chemical compound N1=CNC(C(=O)N[C@@H](C(=O)N[C@@H]2C(N3C(=C(C[N+]=4C=CC(CCS(O)(=O)=O)=CC=4)CS[C@@H]32)C([O-])=O)=O)C=2C=CC=CC=2)=C1C(=O)O LNZMRLHZGOBKAN-KAWPREARSA-N 0.000 description 1
- 229950004036 cefpimizole Drugs 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960003202 cefsulodin Drugs 0.000 description 1
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 1
- 229950000679 cefteram Drugs 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 239000010661 oregano oil Substances 0.000 description 1
- 229940111617 oregano oil Drugs 0.000 description 1
- 239000004482 other powder Substances 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000004562 water dispersible granule Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Mevcut buluş, duyarlı mikroorganizmaların neden olduğu üst solunum yolu enfeksiyonları, alt solunum yolu enfeksiyonları, otitis media, deri ve yumuşak doku enfeksiyonları, kemik ve eklem enfeksiyonları, genitoüriner sistem enfeksiyonları, endokardit, septisemi, dental enfeksiyonlar, farenjit, peritonit, pnömoni, prostatit, sistit, tonsillit, üriner kanal enfeksiyonun semptomatik ve/veya profilaktik ve/veya terapötik tedavisinde sefalosporin antibiyotikleri grubunda yer alan uygun etken maddeyi ve/veya farmasötik olarak kabul edilebilir türevlerini içeren farmasötik bileşim/ler ile ilgilidir.
Description
TARIFNAME
ANTIBAKTERIYEL FORMÜLASYONLAR
BULUSUN ILGILI OLDUGU ALAN
Mevcut bulus, duyarli mikroorganizmalarin neden oldugu üst solunum yolu enfeksiyonlari,
alt solunum yolu enfeksiyonlari, otitis media, deri ve yumusak doku enfeksiyonlari, kemik
ve eklem enfeksiyonlari, genitoüriner sistem enfeksiyonlari, endokardit, septisemi, dental
enfeksiyonlar, farenjit, peritonit, pnömoni, prostatit, sistit, tonsillit, üriner kanal
enfeksiyonun semptomatik ve/veya profilaktik ve/veya terapötik tedavisinde
sefalosporin antibiyotikleri grubunda yer alan uygun etken maddeyi ve/veya farmasötik
olarak kabul edilebilir türevlerini içeren farmasötik bilesim/ler ile ilgilidir.
Mevcut bulus; sefalosporin antibiyotikleri grubunda yer alan uygun etken inadde
Sefaleksin;(7R)-3-Metil-7-(alfa-D-fenilglisilamin0)-3-sefem-4-karboksilik asit monohidrat
(Formül 1) ve/veya farmasötik olarak kabul edilebilir türevleri oldugu ve uygun farmasötik
formlarda etken madde olarak kullanildigi farmasötik bilesim/ler ile ilgilidir.
Formüll:
Ayrica bulus, Sefaleksin ve/veya farmasötik olarak kabul edilebilir türevlerini içeren
bilesimlerin oral uygulama için uygun olan formülasyonlarini seniptomatik ve/veya
profilaktik ve/veya terapötik kullanimlarini da kapsamaktadir.
ÖNCEKI TEKNIK (TEKNIGIN BILINEN DURUMU)
Antibiyotikler; bakterileri yok eden veya gelisimini yavaslatan antimikrobiyal sinifa ait
ilaçlardir. Antibiyotikler kimyasal maddelerden veya mikroorganizmalardan üretilmekte ve
ayrica modern tipta en sik reçete edilen ilaçlar arasinda yer almaktadir. Antibiyotikler
bakterilerin yapilarini hedef alirlar ve bu yapilara baglanirlar. Baglandiklari yapilarda,
bakterinin yasamasi için gerekli olan metabolik olaylari engellerler. Bunun sonucunda
bakteri hücresi ölebilir, ya da büyüme tamamen durur.
Antibiyotik ana siniflari sunlardir:
. Beta-laktam antibiyotikler
o Penisilinler
o Sefalosporinler
- Makrolidler
. Florokinolonlar
o Tetrasiklinler
- Aminoglikozidler
Sefalosporinler genis spektrumlu beta laktam antibiyotiklerdir. Aktivite spektrumlarina
göre birinci, ikinci, üçüncü ve dördüncü kusak olarak siniflandirilirlar. Sefalosporinler
Cephalosporium acremonium (Acremonium chrysogenum) isimli fungustan elde edilen
genis spektrumlu beta laktam antibiyotiklerdir. Bakteri hücre duvari sentezini bozarak etki
ederler. Temel yapisini beta laktam halkanin alti üyeli sülûir içeren dihidrotiyazin
halkasiyla birlesmesi sonucu olusan sefem çekirdegi olusturmaktadir. Temel sefem
halkasinin 1, 3 ve 7 pozisyonlarina yapilan eklemeler ile antibakteriyel ve farmakolojik
özellikleri degismektedir.
US4250166 numarali patent basvurusunda Sefaleksinin oral olarak kullanilan, farkli
farmasötik formlarinin hazirlanmasindan bahsedilmektedir. Ayrica, duyarli
mikroorganizmalarin neden oldugu enfeksiyonlarin tedavisinde kullanildigindan da
bahsedilmektedir.
Sefaleksin, in vitro ve üriner sistem enfeksiyonu tedavisinde degerlendirilmistir. Sefaleksin
Escherichia coli, Proteus mirabilis ve Klebsiella pneumoniae suslarinin % 90'dan fazlasini
inhibe etmek için yeterlidir (Matthew E. Levison, MD; Warren D. Johnson, MD; Thomas
S. Thornhill; Donald Kaye, MD J AMA. 1969;209(9)).
BULUSUN AÇIKLAMASI
Mevcut bulus, duyarli mikroorganizmalarin neden oldugu üst solunum yolu enfeksiyonlari,
alt solunum yolu enfeksiyonlari, otitis media, deri ve yumusak doku enfeksiyonlari, kemik
ve eklem enfeksiyonlari, genitoüriner sistem enfeksiyonlari, endokardit, septisemi, dental
enfeksiyonlar, farenjit, peritonit, pnömoni, prostatit, sistit, tonsillit, üriner kanal
enfeksiyonun semptomatik ve/veya profilaktik ve/veya terapötik tedavisinde
sefalosporin antibiyotikleri grubunda yer alan uygun etken maddeyi ve/veya farmasötik
olarak kabul edilebilir türevlerini içeren farmasötik bilesim/ler ile ilgilidir.
Mevcut bulusun bir diger yönü, oral kullanilmak üzere sefalosporin antibiyotikleri
grubunda yer alan uygun etken maddeyi ve/veya farmasötik olarak kabul edilebilir
türevlerini ve farmasötik olarak kabul edilebilir yardimci maddeleri içeren farmasötik
bilesimlerin hazirlanmasi ile ilgilidir.
Bulusta sefalosporin antibiyotikleri grubunda yer alan etken madde, bunlarla sinirli
olmamakla birlikte, sefiksim, seftriakson, seftazidim, sefoperazon, sefkapen, sefdaloksim,
sefdinir, sefditoren, sefetamet, sefmenoksim, sefodizim, sefotaksim, sefpimizol,
sefpirainid, sefpodoksiin, sefsulodin, sefteram, seftibuten, seftiolen, seftizoksim, sefaleksin
ve/veya farmasötik olarak kabul edilebilir türevleri arasindan tercihen sefaleksin
monohidrat olarak seçilir.
Bulusta “farmasötik olarak kabul edilebilir türevleri” terimi ile farmasötik olarak kabul
edilebilir uygun tuzlar, esterler, solvatlar, hidratlar, kompleksler, polimorflar,
enantiyomerler, önilaçlar, asit adisyon tuzlari, analoglar, izomerler, rasematlar, amidler,
enantiyomer tuzlari, bazik tuzlar, konjugeler, tautomerler, anhidratlar, anhidritler, bazlar,
asitler, eterler, kristal ve amorf formlar veya serbest forrnlarindan bir veya daha fazlasi
ifade edilmektedir.
Oral uygulama için hazirlanan farmasötik bilesim/ler kati ya da sivi dozaj formlarinda
olabilir. Bu dozaj formlari; tablet (çignenebilir tablet, agizda çözünen tablet, dagilabilen
tablet, suda dagilabilen tablet, film kapli tablet, barsakta açilan kaplamali (enterik) tablet,
mini tablet, kontrollü salimli tablet (sürekli salimli tablet, hemen salimli tablet, uzatilmis
salimli tablet, geciktirilmis salimli tablet vb.), kapsül (sert, yumusak, enterik kapli, film
kapli), kontrollü salimli kapsül (sürekli salimli kapsül, hemen salimli kapsül, uzatilmis
salimli kapsül, geciktirilmis salimli kapsül), toz, granül, kaplet, disk, agizda çözünen film,
yigin toz (çok dozlu), pellet, sase, suda dagilabilen toz, suda dagilabilen granül, efervesan
tablet, efervesan granül, efervesan toz, jelül, pilül, surup, solüsyon, süspansiyon, eliksir,
damla, posyon, emülsiyon veya sprey gibi bir dozaj sekli halinde formüle edilebilir.
Bulusta tablet/lerin hazirlanmasinda direk kompresyon, yas veya kuru granülasyon
uygulanabilir.
Direkt kompresyon maddenin fiziksel yapisini bozmadan toz haline getirilmis materyalin
sikistirilmasi ile elde edilmesinden olusmaktadir. Direk sikistirma araci olarak yaygin
sekilde çalisilmis olan yardimci madde mikrokristalin selulozdur (Aviccl, FMC).
Dozaj formlarinin hazirlanmasinda birçok teknikten yararlanilmaktadir. Bunlardan biri de
granülasyon yöntemidir. Granülasyon; ince toz partiküllerin büyümesi seklinde
tanimlanmaktadir. Farmasötik amaçli granülasyon; tabletleme için bir ön hazirlik
asamasidir, ayni zamanda, sert jelatin kapsüle doldurma veya granülün bir final ürün olarak
bir pakete yerlestirilerek kullanimi amaciyla da uygulanmaktadir.
Granülasyonun amaci, karisima istirak eden toz maddenin partiküllerinin birim ilacinin %
miktarlarina esdeger olacak agirlikta bir ünite olusturmaktir. Farmasötik toz karisimlarin
(etken madde veya yardimci maddeler) ayrismalarini engelleyerek bir ünite içerisinde
homojen bir sekilde kalmalarini saglamak gerekmektedir bu da granülasyon ile
mümkündür.
Granülasyonda seçilecek yöntemler 3 ana kategoride siniflandirilabilir: yas granülasyon,
kuru granülasyon ve diger granülasyon yöntemleri.
Yas Granülasyon: Yas granülasyon yönteminde, yüksek hizli akiskan yatak granülasyon,
püskürterek kurutma ve ekstrüsyon pelletleme yöntemleri kullanilmaktadir. Yas
granülasyonda, etken madde ve baglayici madde (solüsyon) belirli sürede karistirilir, yas
olarak elenir ve akiskan yatakli kurutucuda kurutulur. Kurutulan bu karisim diger dolgu
maddeleri ile birlikte belirli bir homojenlige gelinceye kadar karistirilir. Karisimin son 3-5
dakikasinda kaydirici eklenir. Elde edilen final karisimdan örnekler alinir ve laboratuvara
gönderilir. Laboratuvar sonucuna göre tablet basimina yada istenilen farmasötik form için
asamalara geçilebilir.
Yas granülasyon yöntemleri:
1. Yas granülasyon yöntemi (Klasik yöntem)
2. Akiskan yatak yöntemiyle granülasyon
3. Spray-Drying (püskürterek kurutma) yöntemi ile granülasyon
4. Mikrogranülasyon yöntemi
. Ekstrüsyon-Spheronizasyon yöntemi
6. Yüksek hiza sahip karistiricilarla granüle hazirlama yöntemi
Yas granülasyon islemi su sirayi izlemektedir:
° Etken maddenin (gerekli görülür ise) ögütülmesi,
° Toz maddelerle karistirilmasi,
° Baglayici ilavesiyle toz karisimin partiküllerinin kümelesmesinin saglanmasi, (Bu
isleme granülasyon denir.)
° Kümelesmis partiküllerin yas olarak elenmesi,
° Elenmis toz karisiminin kurutulmasi kurutma islemde yaygin alarak akiskan yatakli
kurutucular kullanilmasi,
° Kurutma isleminden sonra kuru ögütme yapilmasi,
° Çift konik ya da V tipi karistiricilarda homojenize edilmesi
° Olusan bu karisima kaydirici ilave edilerek 5 dakika daha karistirilmasi, (Bu
karisima final ürün denir.)
Tablet basimina yada istenilen farmasötik form için asamalara geçilmesidir.
Kuru Granülasyon: Kuru granülasyon yönteminde, ön kompresyon ve silindirler arasi
sikistirma yöntemleri kullanilmaktadir. Kuru granülasyonda genellikle formüldeki
kaydiricinin 1/3,ü diger toz karisimlarina karistirilir. Bunun nedeni tozlarin silindirlere
yapismasini engeller. Kaydiricinin geri kalani kuru granülasyondan sonra karisima eklenir
ve 3-5 dakika karistirilir. Karisim sonrasinda olusan final karisimdan örnekler alinir ve
çesitli testler için laboratuvara gönderilir. Laboratuvar sonucuna göre tablet basimina yada
istenilen farmasötik form için asamalara geçilebilir.
Bulusta kullanilan oral farmasötik süpansiyon hazirlamak için kuru toz formülasyonu;
uygun etken madde/ler yaninda en az bir tamponlayici madde, en az bir koruyucu madde,
en az bir dolgu maddesi/tatlandirici, en az bir Viskozite ajani, en az bir keklesme önleyici
ajan, en az bir aroma verici ajan, en az bir lubrikant ve granülasyon çözücüsünün de dahil
oldugu gruptan seçilen bir veya daha fazla yardimci madde içerebilen bir bilesimi tanimlar.
Bulusta “tamponlayici madde” terimi, kompozisyonun asitlik ve bazligini düzenleyen
maddeler olarak ifade edilmektedir. Tamponlayici madde olarak; sitrik asit anhidrus,
sodyum sitrat dihidrat, sodyum fosfat, sodyum dihidrojen fosfat, potasyum sitrat, fosforik
asit, ainonyum hidroksit, sitrik asit, diizopropanolamin, sodyum karbonat, sodyum silikat,
disodyum ortofosfat, kalsiyum karbonat, magnezyum karbonat, magnezyum hidroksit,
magnezyum alüminat, dietanol amin, sodyum aljinat, etilendiamin, meglümin, hidroklorik
asit, laktik asit, sodyum sitrat dihidrat, sodyum hidroksit, sodyum kloiür, trietanolamin,
trolamine, sodyum benzoat, sodyum hidrojen karbonat veya bunlarin karisimlari
kullanilabilir. Bulusta tercihen sitrik asit anhidrus ve sodyum sitrat dihidrat
kullanilmaktadir. Bulusta kullanilan tamponlayici madde miktari %0.001-5 agirlik
oranindadir.
Bulusta “koruyucu madde” terimi; su ve suda çözünen, yag ve yagda çözünen maddelerin
mikroorganizmalara karsi korunmasini saglayan maddeler olarak ifade edilmektedir.
Koruyucu madde olarak 2-fenoksietanol, sodyum benzoat, benzoik asit, benzil alkol,
etilendiamintetraasetik asit, sodyum metil parahidroksi benzoat, sodyum propil para
hidroksi benzoat, sorbik asit, potasyum sorbat, benzetonyum klorür, klorokresol,
benzalkonyum klorür, butil paraben, metil paraben, propil paraben, etil paraben, butil
hidroksi anisol (BHA), butil hidroksi toluen (BHT), kalsiyum asetat, sitrik asit, disodyum
edetat, gliserin, propil gallat, sodyum bisülfit, sodyum sitrat, sodyum metabisülfit, borik
asit, sorbik asit, sodyum propionat, propilen glikol veya bunlarin karisimlari kullanilabilir.
Bulusta tercihen sodyum benzoat kullanilmaktadir. Bulusta kullanilan koruyucu madde
miktari %0.01-5 agirlik oranindadir.
Bulusta “dolgu maddesi/tatlandirici” terimi; tablet ya da kapsüllerin üretim için pratik,
hasta kullanimina uygun büyüklükte olmasi için kullanilan madde veya madde karisimlari
olarak ifade edilmektedir. Dolgu maddesi olarak; talk, laktoz, sukroz, dekstrin, mannitol,
laktilol, laktitol, ksilitol, sorbitol, izomalt, mikrokristalin selüloz, toz selüloz, dekstroz,
dekstrat, prejelatinize nisasta, modifiye nisasta, misir nisastasi, laktoz anhidröz, laktoz
monohidrat, dibazik kalsiyum fosfat, silisik asit, kaolin, hidroksi propil metilselüloz,
tribazik kalsiyum fosfat, polihidrik alkoller veya selüloz eterleri, kalsiyum hidrojen fosfat
dihidrat, kalsiyum sülfat trihidrat, selüloz kalsiyum sülfat, kalsiyum sülfat dihidrat,
maltodekstrin, kalsiyum karbonat, kaolin, sodyum hidroksit veya bunlarin karisimlari
kullanilabilir. Bulusta tercihen sukroz kullanilmaktadir. Bulusta kullanilan dolgu
maddesi/tatlandirici miktari %10-95 agirlik oranindadir.
Bulusta “Viskozite ajani” terimi, sivinin kalinligini arttirarak yavas akmasini saglayan bir
ajan veya ajan karisimlari olarak ifade edilmektedir. Viskozite ajani olarak; ksantan zamki,
guar zamki, guar galaktomannan, acacia, povidon, aljinik asit, etilselüloz, jelatin,
hidroksietil selüloz, hidroksipropil selüloz, setil alkol, polivinil pirolidon, hidroksi propil
metil selüloz, polidekstroz, karragenan, metil selüloz, sukroz, sorbitol, ksilitol,
hidroksipropil metilselüloz, polivinil alkol, ketearil alkol, kolloidal silikon dioksit veya
bunlarin karisimlari kullanilabilir. Bulusta tercihen ksantan zamki ve guar galaktomannan
kullanilmaktadir. Bulusta kullanilan viskozite ajani miktari %0.01-10 tercihen 0.05-3
agirlik oranindadir.
Bulusta keklesme önleyici ajan olarak; talk, magnezyum stearat, hidrojene nebati yag,
kalsiyum stearat, stearik asit, kolloidal silikon dioksit, sodyum stearilfumarat,
polioksietilenglikol, lösin, letal, sodyum benzoat, sodyum klorür, sodyum asetat, sodyum
fumarat, silika, kolloidal anhidrus silika, polietilenglikol, selüloz türevleri, nisasta, amorf
silika, sentetik amorf silika, silika kolloidal hidrat veya bunlarin karisimlari kullanilabilir.
Bulusta tercihen silika kolloidal hidrat kullanilmaktadir. Bulusta kullanilan keklesme
önleyici ajan miktari %O.1-12 agirlik oranindadir.
Bulusta “aroma verici aj an” terimi, karisima aroma katmak için kullanilan maddeler olarak
ifade edilmektedir. Aroma verici ajan olarak; dogal aroma yaglari (nane yagi, keklik
üzümü yagi, maydanoz yagi, portakal yagi, üzüm, turunç, greyfurt, limon yagi, vb.),
portakal aromasi, muz aromasi, seftali aromasi, greyfurt aromasi, limon aromasi, elma
aromasi, çilek aromasi, krema aromasi, vanilya aromasi, nane aromasi, tutti-furitti aromasi,
frambuaz aromasi, mentol, mentan, anetol, tarçin, metil salisilat, okaliptal, adaçayi,
bögürtlen, sitrus meyvalari veya bunlarin karisimlari kullanilabilir. Bulusta tercihen çilek
aromasi ve krema aromasi kullanilmaktadir. Bulusta kullanilan aroma verici ajan miktari
Bulusta “lubrikant” terimi, sürtünmeyi azaltan veya engelleyen bir toz karisiminin akis
özelliklerini iyilestiren ajan veya ajan karisimlan olarak ifade edilmektedir. Lubrikant
olarak; talk, kalsiyum stearat, magnezyum stearat, alüminyum stearat, polietilen glikol,
tristearin, stearik asit, sodyum lauril sülfat, magnezyum lauril sülfat, kolloidal silikon
dioksit, stearik asit, sodyum stearil fuinarat, polioksietilen glikol, oleik asit, tripalmitil,
potasyum oleat, hidrojene bitkisel yaglar, lösin, alanin, glisin, kaprilik asit, gliseril behenat,
gliseril palmitostearat, sodyum benzoat, sodyum asetat, fumarik asit, çinko stearat, çinko
oleat, çinko palmitat, parafinler, yag alkolleri veya bunlarin karisimlari kullanilabilir.
Bulusta tercihen magnezyum stearat kullanilmaktadir. Bulusta kullanilan lubrikant miktari
Bulusta, granülasyon sivisi olarak saf su, etil alkol, metil alkol, isopropil alkol, butil alkol
gibi alkoller, aseton, diaseton, polioller, polieterler, esterler, alkil ketonlar, metilen klorür,
metil asetat, etil asetat, izopropil asetat, kastor yagi, etilen glikol monoetil eter, dietilen
glikol monobutil eter, dietilen glikol monoetil eter, dimetil sülfoksit, dimetil formamid,
tetrahidrofuran veya bunlarin karisimlari kullanilabilir. Bulusta tercihen saf su
kullanilmaktadir.
Mevcut bulustaki Sefaleksin ve/veya farmasötik olarak kabul edilebilir türevlerini içeren
farmasötik bilesimler için uygun olan formülasyonlarina ait doz araligi; 50-2000mg
uzmanin degerlendirmesine göre ayarlanmaktadir.
Bulusta, Sefaleksin ve/veya farmasötik olarak kabul edilebilir türevlerinin kullanildigi
farmasötik bilesimlerin oral uygulamasina yönelik süspansiyon hazirlamak için kuru toz
formülasyonu asagidakileri içermektedir;
- yaklasik %0.1-35 agirlik oraninda Sefaleksin monohidrat
- yaklasik %0.001-5 agirlik oraninda sitrik asit anhidrus ve sodyum sitrat dihidrat
- yaklasik %0.01-5 agirlik oraninda sodyum benzoat
- yaklasik %10-95 agirlik oraninda sukroz
- yaklasik %0.01-10 agirlik oraninda ksantan zamki ve guar galaktomannan
- yaklasik %0.1-12 agirlik oraninda silika kolloidal hidrat
- yaklasik %0.01-5 agirlik oraninda çilek aromasi ve krema aromasi
- yaklasik%0.0l-6 agirlik oraninda magnezyum stearat
- kafi miktar saf su
Bulus esas olarak, oral kullanilmak üzere sefalosporin antibiyotikleri grubunda yer alan
uygun etken maddeyi ve/veya farmasötik olarak kabul edilebilir türevlerini ve farmasötik
olarak kabul edilebilir yardimci maddeleri içeren farmasötik bilesim/lerin hazirlanmasi ile
ilgilidir. Söz konusu farmasötik formülasyonlarin oral süspansiyon hazirlamak için kuru
toz formunda olmasi temeldir. Böylece Sefaleksin ve/veya farmasötik olarak kabul
edilebilir türevleri ile hazirlanan uygun farmasötik formlar sasirtici bir sekilde fiziksel ve
kimyasal kararlilik açisindan oldukça stabil bir davranis sergilemistir.
Bulusun özellikleri asagidakilerle sinirli kalmamak üzere örnekler asagida verilmistir:
Sefaleksin ve/veya farmasötik olarak kabul edilebilir türevlerinin kullanildigi farmasötik
bilesimlerin oral uygulamasina yönelik süspansiyon hazirlamak için kuru toz formülasyonu
asagidakileri içermektedir;
- yaklasik %0.1-35 agirlik oraninda Sefaleksin monohidrat
- yaklasik %0.001-5 agirlik oraninda sitrik asit anhidrus ve sodyum sitrat dihidrat
- yaklasik %0.01-5 agirlik oraninda sodyum benzoat
- yaklasik %10-95 agirlik oraninda sukroz
- yaklasik %0.01-10 agirlik oraninda ksantan zamki ve guar galaktomannan
- yaklasik %0. 1-12 agirlik oraninda silika kolloidal hidrat
- yaklasik %0.01-5 agirlik oraninda çilek aromasi ve krema aromasi
- yaklasik%0.01-6 agirlik oraninda magnezyum stearat
- kafi miktar saf su
Sefaleksin ve/veya farmasötik olarak kabul edilebilir türevlerinin kullanildigi faimasötik
bilesimlerin oral uygulamasina yönelik süspansiyon hazirlamak için kuru toz formülasyonu
asagidakileri içermektedir;
- yaklasik l-lOOOmg Sefaleksin monohidrat
- yaklasik 0.01-20mg sitrik asit anhidrus ve sodyum sitrat dihidrat
-yaklasik 0.1-35mg sodyum benzoat
- yaklasik 40-5500mg sukroz
- yaklasik 0.1-45mg ksantan zamki ve guar galaktomannan
- yaklasik 0.5-90mg silika kolloidal hidrat
- yaklasik 0.5-160mg çilek aromasi ve krema aromasi
- yaklasik 0.1-50mg magnezyum stearat
- kafi miktar saf su
Üretim prosesi:
Hammaddeler üretim formülüne uygun tartilir. Üretim formülüne uygun tartilmis olan
sodyum benzoat, saf su içerisinde çözündürülür (granülasyon çözeltisi). Granülasyon için
uygun miktarda tartilmis olan sukroz granülatöre aktarilip ön karisim yapilir, granülasyon
çözeltisi aktarilarak granülasyon tamamlanir. Elde edilen granüller uygun kurutucuda
kurutulur. Kuruyan granüller uygun sekilde elekten elenir.
Hazirlanmis olan sukroz granülünün üzerine sitrik asit anhidrus, sodyum sitrat dihidrat ve
sukroz granülünün belirli bir kismi uygun yöntem ile uygun karistirici da karistirilir
(Karisim-l). Karisim-Fin üzerine ksantan zamki, guar galaktomannan silika kolloidal
hidrat, çilek aromasi ve krema aromasi ilave edilip karistirilir (Karisim-2). Karisim-?nin
üzerine, sefaleksin monohidrat ile beraber sukroz uygun araliktaki elekten elenmis sekilde
ilave edilip karistirilir (Karisim-3). Üretim formülüne uygun tartim olan dis faz Sukroz,un
belirli bir kismi uygun elekten elenir. Kalan sukroz granülü, dis faz için elenmis olan
sukroz ve Karisim-3 uygun yöntem ile konteynira ilave edilerek karistirilir. Elekten
elenmis olan magnezyum stearat ilave edilip karistirilir. Final karisim sonrasi elde edilen
bulk tozdan uygun miktarda sise/lere uygun olacak sekilde dolum yapilir.
Claims (1)
- ISTEMLER . Oral kullanilmak üzere sefalosporin antibiyotikleri grubunda yer alan uygun etken maddeyi ve/veya farmasötik olarak kabul edilebilir türevlerini ve farmasötik olarak kabul edilebilir yardimci maddeleri içeren farmasötik bilesim/lerin hazirlanmasi. Istem 1, de belirtilen farmasötik bilesim/ler olup özelligi; sefalosporin antibiyotikleri grubunda yer alan uygun etken maddenin sefiksim, seftriakson, seftazidim, sefoperazon, sefkapen, sefdaloksim, sefdinir, sefditoren, sefetamet, sefmenoksim, sefodizim, sefotaksim, sefpimizol, sefpiramid, sefpodoksim, sefsulodin, sefteram, seftibuten, seftiolen, seftizoksim, sefaleksin ve/veya farmasötik olarak kabul edilebilir türevleri arasindan seçilmesidir. . Istem l,de belirtilen farmasötik bilesim/ler olup özelligi; sefalosporin antibiyotikleri grubunda yer alan uygun etken maddenin tercihen sefaleksin monohidrat olmasidir. . Sefaleksin ve/veya farmasötik olarak kabul edilebilir türevlerinin kullanildigi farmasötik bilesimlerin oral uygulamasina yönelik süspansiyon hazirlamak için kuru toz formülasyonu asagidakileri içermektedir; - yaklasik %O.1-35 agirlik oraninda Sefaleksin monohidrat - yaklasik %0.001-5 agirlik oraninda sitrik asit anhidrus ve sodyum sitrat dihidrat - yaklasik %0.01-5 agirlik oraninda sodyum benzoat - yaklasik %10-95 agirlik oraninda sukroz - yaklasik %0.01-10 agirlik oraninda ksantan zamki ve guar galaktomannan - yaklasik %O.1-12 agirlik oraninda silika kolloidal hidrat - yaklasik %0.01-5 agirlik oraninda çilek aromasi ve krema aromasi - yaklasik%0.01-6 agirlik oraninda magnezyum stearat - kafi miktar saf su . Sefaleksin ve/veya farmasötik olarak kabul edilebilir türevlerinin kullanildigi farmasötik bilesimlerin oral uygulamasina yönelik süspansiyon hazirlamak için kuru toz formülasyonu asagidakileri içermektedir; - yaklasik %0. 1-35 agirlik oraninda Sefaleksin monohidrat - yaklasik %0.001-5 agirlik oraninda sitrik asit anhidrus ve sodyum sitrat dihidrat - yaklasik %0.01-5 agirlik oraninda sodyum benzoat - yaklasik %10-95 agirlik oraninda sukroz - yaklasik %0.01-10 agirlik oraninda ksantan zamki ve guar galaktomannan - yaklasik %O.1-12 agirlik oraninda silika kolloidal hidrat - yaklasik %0.0l-5 agirlik oraninda çilek aromasi ve krema aromasi - yaklasik%0.01 -6 agirlik oraninda magnezyum stearat - kafi miktar saf su Istem 4,de belirtilen farmasötik bilesim/ler olup özelligi; tamponlayici maddenin sitrik asit anhidrus, sodyum sitrat dihidrat, sodyum fosfat, sodyum dihidrojen fosfat, potasyum sitrat, fosforik asit, amonyum hidroksit, sitrik asit, diizopropanolamin, sodyum karbonat, sodyum silikat, disodyum ortofosfat, kalsiyum karbonat, magnezyum karbonat, magnezyum hidroksit, magnezyum alüminat, dietanol amin, sodyum aljinat, etilendiamin, meglümin, hidroklorik asit, laktik asit, sodyum sitrat dihidrat, sodyum hidroksit, sodyum klorür, trietanolamin, trolamine, sodyum benzoat, sodyum hidrojen karbonat veya bunlarin karisimlari arasindan seçilmesidir. Istem 6,da belirtilen farmasötik bilesim/ler olup özelligi; tamponlayici maddenin tercihen sitrik asit anhidrus ve sodyum sitrat dihidrat olmasidir. Istem 4”de belirtilen farmasötik bilesim/ler olup özelligi; koruyucu maddenin 2- fenoksietanol, sodyum benzoat, benzoik asit, benzil alkol, etilendiamintetraasetik asit, sodyum metil parahidroksi benzoat, sodyum propil para hidroksi benzoat, sorbik asit, potasyum sorbat, benzetonyum klorür, klorokresol, benzalkonyum klorür, butil paraben, metil paraben, propil parabeii, etil paraben, butil hidroksi aiiisol (BHA), butil hidroksi toluen (BHT), kalsiyum asetat, sitrik asit, disodyum edetat, gliserin, propil gallat, sodyum bisülfit, sodyum sitrat, sodyum metabisülfit, borik asit, sorbik asit, sodyum propionat, propilen glikol veya bunlarin karisimlari arasindan seçilmesidir. Istem 8,de belirtilen farmasötik bilesim/ler olup özelligi; koruyucu maddenin tercihen sodyum benzoat olmasidir. Istem 47de belirtilen farmasötik bilesim/ler olup özelligi; dolgu maddesinin talk, laktoz, sukroz, dekstriii, mannitol, laktilol, laktitol, ksilitol, sorbitol, izomalt, inikrokristalin selüloz, toz selüloz, dekstroz, dekstrat, prejelatinize nisasta, modifiye nisasta, misir nisastasi, laktoz anhidröz, laktoz monohidrat, dibazik kalsiyum fosfat, silisik asit, kaolin, hidroksi propil metilselüloz, tribazik kalsiyum fosfat, polihidrik alkoller veya selüloz eterleri, kalsiyum hidrojen fosfat dihidrat, kalsiyum sülfat trihidrat, selüloz kalsiyum sülfat, kalsiyum sülfat dihidrat, maltodekstrin, kalsiyum karbonat, kaolin, sodyum hidroksit veya bunlarin karisimlari arasindan seçilmesidir. Istem 10lda belirtilen farmasötik bilesim/ler olup özelligi; dolgu maddesinin tercihen sukroz olmasidir. Istem 4lde belirtilen farmasötik bilesim/ler olup Özelligi; Viskozite ajaninin ksantan zamki, guar zamki, guar galaktomannan, acacia, povidon, aljinik asit, etilselüloz, jelatin, hidroksietil selüloz, hidroksipropil selüloz, setil alkol, polivinil pirolidon, hidroksi propil metil selüloz, polidekstroz, karragenan, metil selüloz, sukroz, sorbitol, ksilitol, hidroksipropil metilselüloz, polivinil alkol, ketearil alkol, kolloidal silikon dioksit veya bunlarin karisimlari arasindan seçilmesidir. Istem 12lde belirtilen farmasötik bilesim/ler olup özelligi; Viskozite ajaninin tercihen ksantan zamki ve guar galaktomannan olmasidir. Istem 4,de belirtilen farmasötik bilesim/ler olup özelligi; keklesme önleyici ajanin talk, magnezyum stearat, hidrojene nebati yag, kalsiyum stearat, stearik asit, kolloidal silikon dioksit, sodyum stearilfumarat, polioksietilenglikol, lösin, letal, sodyum benzoat, sodyum klorür, sodyum asetat, sodyum fumarat, silika, kolloidal anhidrus silika, polietilenglikol, selüloz türevleri, nisasta, amorf silika, sentetik amorf silika, silika kolloidal hidrat veya bunlarin karisimlari arasindan seçilmesidir. Istem 14,de belirtilen farmasötik bilesim/ler olup özelligi; keklesme önleyici ajanin tercihen silika kolloidal hidrat olmasidir. Istem 43de belirtilen farmasötik bilesim/ler olup özelligi; aroma verici ajanin dogal aroma yaglari (nane yagi, keklik üzümü yagi, maydanoz yagi, portakal yagi, üzüm, turunç, greyfurt, limon yagi, vb.), portakal aromasi, muz aromasi, seftali aromasi, greyfurt aromasi, limon aromasi, elma aromasi, çilek aromasi, krema aromasi, vanilya aromasi, nane aromasi, tutti-furitti aromasi, frambuaz aromasi, mentol, mentan, anetol, tarçin, metil salisilat, okaliptal, adaçayi, bögürtlen, sitrus meyvalari veya bunlarin karisimlari arasindan seçilmesidir. Istem l6”da belirtilen farmasötik bilesim/ler olup özelligi; aroma verici ajanin tercihen çilek aromasi ve krema aromasi olmasidir. Istem 4°de belirtilen farmasötik bilesim/ler olup özelligi; lubrikantin talk, kalsiyum stearat, magnezyum stearat, alüminyum stearat, polietilen glikol, tristearin, stearik asit, sodyum lauril sülfat, magnezyum lauril sülfat, kolloidal silikon dioksit, stearik asit, sodyum stearil fumarat, polioksietilen glikol, oleik asit, tripalmitil, potasyum oleat, hidrojene bitkisel yaglar, lösin, alanin, glisin, kaprilik asit, gliseril behenat, gliseril palmitostearat, sodyum benzoat, sodyum asetat, fumarik asit, çinko stearat, çinko oleat, çinko palmitat, parafinler, yag alkolleri veya bunlarin karisimlari arasindan seçilmesidir. Istem 18,de belirtilen farmasötik bilesim/ler olup özelligi; lubrikantin tercihen magnezyum stearat olmasidir. Istem 4,de belirtilen farmasötik bilesim/ler olup özelligi; granülasyon sivisinin saf su, etil alkol, metil alkol, isopropil alkol, butil alkol gibi alkoller, aseton, diaseton, polioller, polieterler, esterler, alkil ketonlar, metilen klorür, metil asetat, etil asetat, izopropil asetat, kastor yagi, etilen glikol monoetil eter, dietilen glikol monobutil eter, dietilen glikol monoetil eter, dimetil sülfoksit, dimetil formamid, tetrahidrofuran veya bunlarin karisimlari arasindan seçilmesidir. Istem 4,de belirtilen farmasötik bilesim/ler olup özelligi; granülasyon sivisinin tercihen saf su olmasidir. Yukarida belirtilen istemlerden herhangi birine göre farmasötik bilesim/ler olup özelligi; Sefaleksin ve/veya farmasötik olarak kabul edilebilir türevlerini içeren farmasötik bilesimleri için uygun olan formülasyonlarina ait doz araliginin; 50-2000mg olmasidir. Yukarida belirtilen istemlerden herhangi birine göre farmasötik bilesim/ler olup özelligi; duyarli mikroorganizmalarin neden oldugu üst solunum yolu enfeksiyonlari, alt solunum yolu enfeksiyonlari, otitis media, deri ve yumusak doku enfeksiyonlari, kemik ve eklem enfeksiyonlari, genitoüriner sistem enfeksiyonlari, endokardit, septisemi, dental enfeksiyonlar, farenjit, peritonit, pnömoni, prostatit, sistit, tonsillit, üriner kanal enfeksiyonun semptomatik ve/veya profilaktik ve/veya terapötik tedavisinde endike olmasidir.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2016/05717A TR201605717A1 (tr) | 2016-05-02 | 2016-05-02 | Anti̇bakteri̇yel formülasyonlar |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2016/05717A TR201605717A1 (tr) | 2016-05-02 | 2016-05-02 | Anti̇bakteri̇yel formülasyonlar |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201605717A1 true TR201605717A1 (tr) | 2017-11-21 |
Family
ID=67000179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2016/05717A TR201605717A1 (tr) | 2016-05-02 | 2016-05-02 | Anti̇bakteri̇yel formülasyonlar |
Country Status (1)
Country | Link |
---|---|
TR (1) | TR201605717A1 (tr) |
-
2016
- 2016-05-02 TR TR2016/05717A patent/TR201605717A1/tr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5943915B2 (ja) | リファキシミンの製剤およびその使用 | |
US20170216305A1 (en) | Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain | |
ES2389358T5 (es) | Composiciones farmacéuticas de rifaximina | |
US9498442B2 (en) | Rifaximin powder, process for preparing the same an controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect | |
KR20200000462A (ko) | 경구 투여를 위한 리나클로타이드-함유 제형 | |
JP2007091633A (ja) | メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物 | |
EP3616696A1 (en) | Orally administrable enzalutamide-containing pharmaceutical composition | |
TW201322979A (zh) | 醫藥組成物 | |
KR20010080566A (ko) | 세푸록심 악세틸을 포함하는 조성물 | |
JP2020506245A (ja) | ラモトリギン懸濁液剤形 | |
BRPI0709710A2 (pt) | composiÇço oral, e, soluÇço aquosa oral | |
CN107625754B (zh) | 一种头孢泊肟酯掩味颗粒及其制备方法 | |
US7666860B2 (en) | Melt-formulated, multi-particulate oral dosage form | |
UA82268C2 (uk) | Гранули, що містять гідрохлорид венлафаксину, та спосіб їх виготовлення | |
KR100783286B1 (ko) | 클로피도그렐 우선성 광학이성체의 유리염기를 함유하는고형의 약제학적 조성물 | |
EA036278B1 (ru) | Фармацевтическая композиция | |
EP2263671B1 (en) | Amide derivative-containing pharmaceutical composition | |
US20150072014A1 (en) | Pharmaceutical Compositions of Sodium Picosulfate, Magnesium Oxide and Citric Acid | |
EP3290037A1 (en) | Pharmaceutical composition for oral administration | |
TR201605717A1 (tr) | Anti̇bakteri̇yel formülasyonlar | |
FI89455C (fi) | Foerfarande foer framstaellning av en farmaceutisk komposition | |
TR201511982A2 (tr) | Anti̇bakteri̇yel formülasyonlar | |
MXPA05003357A (es) | Composicion medicinal antibacteriana de capacidad de absorcion oral mejorada. | |
US9775832B2 (en) | Pharmaceutical composition for oral administration | |
PT1671635E (pt) | Composição de antibiótico amorfo contendo cefditoreno pivoxil |